BACKGROUND AND AIMS: Although the anticancer effects of rapamycin (RPM) and 5-aza-deoxycytidine (AZA) have been studied extensively, the combined effect of these two drugs on colorectal cancer (CRC) is still unknown. This study addresses the effect of AZA and RPM combination therapy on CRC and its influence on the mammalian target of rapamycin (mTOR) and its signal transduction pathway. SUBJECTS AND METHODS: Human CRC cell line HCT116 was treated with AZA alone, RPM alone, or concurrently with a combination of both drugs. Cell viability, apoptosis, and cell cycle distribution were analyzed. CRC was initiated in S-ICR mice, which were then treated with the drugs mentioned above, and tumor incidence and volume were measured. The activity of the mTOR signal transduction pathway was detected by Western blot analysis or immunohistochemistry. RESULTS: Combination treatment with AZA and RPM inhibited the growth of HCT116 cells, induced apoptosis, arrested the cell cycle, and reduced the incidence and tumor volume of CRC in mice, as well as inhibited the phosphorylation of components of the mTOR signal transduction pathway. These effects were more significant than those of single-drug treatments. CONCLUSION: Combination treatment with AZA and RPM inhibits the formation and growth of CRC. These findings may provide a novel strategy for CRC treatment.
BACKGROUND AND AIMS: Although the anticancer effects of rapamycin (RPM) and 5-aza-deoxycytidine (AZA) have been studied extensively, the combined effect of these two drugs on colorectal cancer (CRC) is still unknown. This study addresses the effect of AZA and RPM combination therapy on CRC and its influence on the mammalian target of rapamycin (mTOR) and its signal transduction pathway. SUBJECTS AND METHODS: Human CRC cell line HCT116 was treated with AZA alone, RPM alone, or concurrently with a combination of both drugs. Cell viability, apoptosis, and cell cycle distribution were analyzed. CRC was initiated in S-ICR mice, which were then treated with the drugs mentioned above, and tumor incidence and volume were measured. The activity of the mTOR signal transduction pathway was detected by Western blot analysis or immunohistochemistry. RESULTS: Combination treatment with AZA and RPM inhibited the growth of HCT116 cells, induced apoptosis, arrested the cell cycle, and reduced the incidence and tumor volume of CRC in mice, as well as inhibited the phosphorylation of components of the mTOR signal transduction pathway. These effects were more significant than those of single-drug treatments. CONCLUSION: Combination treatment with AZA and RPM inhibits the formation and growth of CRC. These findings may provide a novel strategy for CRC treatment.
Authors: Michael T McCabe; Jonathan A Low; Stephanie Daignault; Michael J Imperiale; Kirk J Wojno; Mark L Day Journal: Cancer Res Date: 2006-01-01 Impact factor: 12.701
Authors: Jairo Rodriguez; Jordi Frigola; Elisenda Vendrell; Rosa-Ana Risques; Mario F Fraga; Cristina Morales; Victor Moreno; Manel Esteller; Gabriel Capellà; Maria Ribas; Miguel A Peinado Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701
Authors: Elizabeth Buck; Alexandra Eyzaguirre; Eric Brown; Filippo Petti; Siobhan McCormack; John D Haley; Kenneth K Iwata; Neil W Gibson; Graeme Griffin Journal: Mol Cancer Ther Date: 2006-11 Impact factor: 6.261
Authors: Teruaki Fujishita; Koji Aoki; Heidi A Lane; Masahiro Aoki; Makoto M Taketo Journal: Proc Natl Acad Sci U S A Date: 2008-09-03 Impact factor: 11.205
Authors: Giovanni Vitale; Alessandra Dicitore; Daniele Pepe; Davide Gentilini; Elisa S Grassi; Maria O Borghi; Giulia Gelmini; Maria C Cantone; Germano Gaudenzi; Gabriella Misso; Anna M Di Blasio; Leo J Hofland; Michele Caraglia; Luca Persani Journal: Mol Oncol Date: 2017-06-21 Impact factor: 6.603
Authors: Peter Tan; Ing Soo Tiong; Shaun Fleming; Giovanna Pomilio; Nik Cummings; Mark Droogleever; Julie McManus; Anthony Schwarer; John Catalano; Sushrut Patil; Sharon Avery; Andrew Spencer; Andrew Wei Journal: Oncotarget Date: 2016-11-29